Análisis temático documental

por CASTAÑÓN MORENO, BLANCA
Publicado 1992

A Data-Weighted Prior Estimator for Forecast Combination

por Fernández-Vázquez, Esteban, Moreno, Blanca, Hewings, Geoffrey J.D.
Publicado 2019

Combined treatment with dabrafenib and trametinib with immune-stimulating antibodies for BRAF mutant melanoma

por Homet Moreno, Blanca, Mok, Stephen, Comin-Anduix, Begonya, Hu-Lieskovan, Siwen, Ribas, Antoni
Publicado 2015

Linear Elastic Fracture Mechanics Assessment of a Gas Turbine Vane

por Orenes Moreno, Blanca, Bessone, Andrea, Solazzi, Simone, Vanti, Federico, Bagnera, Francesco, Riva, Andrea, Botto, Daniele
Publicado 2022

Temporal changes in treatment patterns by age group and functional status before and after PD-1/L1 inhibitor approvals in advanced urothelial carcinoma

por Doshi, Gurjyot K., Li, Haojie, Burcu, Mehmet, Annavarapu, Srinivas, Wells, Karen, Imai, Kentaro, Moreno, Blanca Homet, Singhal, Puneet, Mamtani, Ronac
Publicado 2023

MAPK pathway inhibition induces MET and GAB1 levels, priming BRAF mutant melanoma for rescue by hepatocyte growth factor

por Caenepeel, Sean, Cooke, Keegan, Wadsworth, Sarah, Huang, Guo, Robert, Lidia, Moreno, Blanca Homet, Parisi, Giulia, Cajulis, Elaina, Kendall, Richard, Beltran, Pedro, Ribas, Antoni, Coxon, Angela, Hughes, Paul E.
Publicado 2017

Isolation and characterization of NY-ESO-1–specific T cell receptors restricted on various MHC molecules

por Bethune, Michael T., Li, Xiao-Hua, Yu, Jiaji, McLaughlin, Jami, Cheng, Donghui, Mathis, Colleen, Moreno, Blanca Homet, Woods, Katherine, Knights, Ashley J., Garcia-Diaz, Angel, Wong, Stephanie, Hu-Lieskovan, Siwen, Puig-Saus, Cristina, Cebon, Jonathan, Ribas, Antoni, Yang, Lili, Witte, Owen N., Baltimore, David
Publicado 2018

Standard-Dose Pembrolizumab Plus Alternate-Dose Ipilimumab in Advanced Melanoma: KEYNOTE-029 Cohort 1C, a Phase 2 Randomized Study of Two Dosing Schedules

por Long, Georgina V., Robert, Caroline, Butler, Marcus O., Couture, Felix, Carlino, Matteo S., O'Day, Steven, Atkinson, Victoria, Cebon, Jonathan S., Brown, Michael P., Dalle, Stéphane, Hill, Andrew G., Gibney, Geoffrey T., McCune, Steven, Menzies, Alexander M., Niu, Cuizhen, Ibrahim, Nageatte, Moreno, Blanca Homet, Diab, Adi
Publicado 2021

Long-term outcomes in patients with advanced melanoma who had initial stable disease with pembrolizumab in KEYNOTE-001 and KEYNOTE-006

por Hamid, Omid, Robert, Caroline, Daud, Adil, Carlino, Matteo S., Mitchell, Tara C., Hersey, Peter, Schachter, Jacob, Long, Georgina V., Hodi, F. Stephen, Wolchok, Jedd D., Arance, Ana, Jacques Grob, Jean, Joshua, Anthony M., Weber, Jeffrey S., Mortier, Laurent, Jensen, Erin, Diede, Scott J., Homet Moreno, Blanca, Ribas, Antoni
Publicado 2021

Interferon Receptor Signaling Pathways Regulating PD-L1 and PD-L2 Expression

por Garcia-Diaz, Angel, Shin, Daniel Sanghoon, Moreno, Blanca Homet, Saco, Justin, Escuin-Ordinas, Helena, Rodriguez, Gabriel Abril, Zaretsky, Jesse M., Sun, Lu, Hugo, Willy, Wang, Xiaoyan, Parisi, Giulia, Saus, Cristina Puig, Torrejon, Davis Y., Graeber, Thomas G., Comin-Anduix, Begonya, Hu-Lieskovan, Siwen, Damoiseaux, Robert, Lo, Roger S., Ribas, Antoni
Publicado 2017

Three-year survival, correlates and salvage therapies in patients receiving first-line pembrolizumab for advanced Merkel cell carcinoma

por Nghiem, Paul, Bhatia, Shailender, Lipson, Evan J, Sharfman, William H, Kudchadkar, Ragini R, Brohl, Andrew S, Friedlander, Philip A, Daud, Adil, Kluger, Harriet M, Reddy, Sunil A, Boulmay, Brian C, Riker, Adam, Burgess, Melissa A, Hanks, Brent A, Olencki, Thomas, Kendra, Kari, Church, Candice, Akaike, Tomoko, Ramchurren, Nirasha, Shinohara, Michi M, Salim, Bob, Taube, Janis M, Jensen, Erin, Kalabis, Mizuho, Fling, Steven P, Homet Moreno, Blanca, Sharon, Elad, Cheever, Martin A, Topalian, Suzanne L
Publicado 2021